Aims: Bcell lymphoma 9 (BCL9)-Wnt/β-catenin pathway, a key signaling pathway related to epithelial-mesenchymal transition (EMT), is widely considered to be involved in invasion in various malignant tumors. However, the dysregulation of BCL9/β-catenin pathway in non-small cell lung cancer (NSCLC) has not been revealed. This study aimed to investigate the correlation between chemotherapy resistance and BCL9/Wnt/β-catenin signaling dysfunction. Main methods: We performed BCL9 knockdown using a lentivirus-mediated sh-RNA interference in cisplatinresistant (CR) lung cancer cells. Subsequently, the migration and invasion were determined by wound-healing and Transwell assays. Furthermore, EMT markers and β-catenin were examined by Western blot. Immunofluorescence was used to investigate the subcellular localization of β-catenin. The chemotherapeutic sensitivity to cisplatin in A549/DDP cell lines after treatment with BCL9 sh-RNA was estimated by MTT assay. Key findings: The knockdown of BCL9 remarkably reduced the migration and invasion abilities of A549/DDP cells. Meanwhile, nuclear translocation of β-catenin was reduced after BCL9 was knocked down. BCL9 silencing also resulted in the downregulation of EMT-related proteins. Additionally, the Wnt/β-catenin agonist, CP21, significantly restored the expression of β-catenin and abilities of migration and invasion in BCL9-knockdown A549/DDP cell lines. Finally, we proved that the inhibition of BCL9 could partially attenuate the stemness of cancer cells and recover the chemotherapeutic sensitivity. Significance: These findings indicated BCL9 induced the occurrence of EMT and enhancement of stemness, which resulted in cisplatin-resistance and promoted migration in NSCLC cells. Mechanically, Wnt/β-catenin pathway is crucial in BCL9-induced migration, invasion, and chemotherapy resistance.
Introduction
Non-small cell lung cancer (NSCLC) accounts for over 80% of cases of lung carcinoma worldwide. In China, lung cancer has been the primary reason for cancer deaths in both men and women [1] . The low 5-year survival rate in patients with NSCLC despite the utilization of multidisciplinary therapy is attributed to the chemotherapeutic resistance and rapid metastasis from the primary tumor to lymph nodes and remote organs [2] [3] [4] . Therefore, it is essential to address the mechanisms associated with the rapid progression of chemotherapy-resistant NSCLC and propose novel potential therapeutic targets.
Disorder in the Wnt/β-catenin pathway was defined as one of the underlying causes for epithelial-mesenchymal transition (EMT) in a wide range of malignant tumors [5] [6] [7] . Previous studies have shown that EMT induces metastasis and invasion by the destruction of the epithelial adherent junction, enhancement of the expression of matrix metalloproteinases, and promoting the formation of vasculogenic mimicry in NSCLC [8] , which results in strong invasiveness and poor prognosis. The inhibition of Wnt/β-catenin pathway therefore has been considered as a promising therapeutic strategy. Although several drugs have been verified to inhibit the pathway, these inhibitors lack a safe therapeutic window because of the dose-limited toxicity, which has been elucidated from the important roles of Wnt/β-catenin pathway in the maintenance of normal tissue homeostasis and physiological functions. Therefore, these conventional non-selective inhibitors can't be regarded as appropriate agents for in vivo experiments and clinical https://doi.org/10.1016/j.lfs.2018.07.023 Received 16 March 2018; Received in revised form 10 July 2018; Accepted 12 July 2018 applications [9, 10] .
The canonical Wnt pathway is a receptor-mediated signal transduction network required for both normal embryonic development and cancerous cells survival. Its activity was regulated by the expression, localization, and phosphorylation of β-catenin [5, 6] . In the absence of Wnt ligands, β-catenin binds to adenomatous polyposis coli (APC), glycogen synthase kinase 3β (GSK3β), and Axin to form a destruction complex that phosphorylates β-catenin, which targets it for proteasomal degradation [9] . Binding of Wnt ligands to the Frizzled and Lowdensity lipoprotein receptors (LRP5 and LRP6) inhibits the activity of the APC/GSK3β/Axin complex, enabling non-phosphorylated β-catenin to undergo nuclear translocation for regulation of transcription. CP21R7 (CP21), an agonist of Wnt/beta-catenin used in this study, is a small molecular selective inhibitor of GSK3β. CP21R7 potently activates canonical Wnt signaling via inhibition of formation of destruction complex that phosphorylated and degraded beta-catenin via interaction with GSK3β, APC and Axin. Therefore, the administration of CP21 would significantly increase actual total levels of intracellular β-catenin and possibly partly block the effect of BCL9 shRNA in NSCLC cells.
B-cell lymphoma 9 (BCL9) was first identified by cloning the (t1; t14) (q21; q32) translocation and has been deemed as an oncogene that is associated with tumor progression. In patients with colon carcinoma, overexpression of BCL9 has been commonly observed and associated with the poor survival prognosis [11] [12] [13] . Meanwhile up-regulation of BCL9 has been proved to accelerate the progression of colon tumor in transgenic mouse models by excessive augmentation of the transcription levels of β-catenin. Interestingly, the deletion of BCL9/9l could not lead to the detectable conversion of normal phenotype, thereby suggesting that the BCL9 does not play a vital role in maintaining the normal tissue homeostasis [13] . In addition, BCL9 is absent in normal colon tissue. These results indicated that the BCL9 might be a potential selective target owing to its absence in non-cancerous tissue and the independence of normal physiological function [13] .
In the current study, we investigated the correlation between chemotherapy resistance and the dysregulation of BCL9/Wnt/β-catenin. Our results suggest that BCL9 induces the EMT by the activation of β-catenin in chemotherapy-resistant NSCLC cell lines, whereas BCL9 silencing suppresses the metastasis of cancer cells (CSCs) through the inhibition of EMT and enhances the recovery of the sensitivity to chemotherapeutic drugs. More importantly, a highly selective inhibitor of BCL9 may be served as a potential therapeutic strategy in chemotherapy-resistant NSCLC.
Method

Cell culture
The human NSCLC cell lines, NCI-H460 (wild type) and A549-DDP were purchased from Zhongyuan Biotechnology Co., Ltd. (Beijing, China) and Xinyu Biotechnology Co., Ltd. (Shanghai, China). Cells were cultured in medium (RPMI-1640) containing 10% FBS (Invitrogen). In addition, the cultured medium was supplied with 1000 U/L penicillin and 1000 U/L streptomycin and maintained at 37°C in a humidified incubator containing 5% CO 2 and 95% humidity.
Transfection in the NSCLC cell lines
Lentivirus-mediated shRNA was applied to knockdown BCL9 in A549-DDP cell line and primary NSCLC cells from patient according to Liposome Transfection. The negative control (NC) was constructed using scrambled shRNA that were incapable of silencing the gene. ShRNA was obtained from GeneChem (Shanghai, China). The transfection was processed according to the standard procedure. A549-DDP cells were seeded on 96-well plates (5000 cells/well) and incubated in incubator. On the second day, the cells were transfected with lentivirus vector constructed by BCL9-shRNA (CCTCTGTTGAATATCCCTGGAA) or NC-shRNA (AGCGTGGGTGGGGTCCGTCC) for 10-12 h by using Lipofectamine reagents (Invitrogen). The cells with green fluorescence indicated stable transfection with lentivirus-mediated shRNA. In total, > 85% cells were examined with green fluorescence under a fluorescence microscope, thereby indicating a successful establishment of the cell models, classified as A549-NC and A549-BCL9-KD (knockdown), respectively.
Transfection in primary NSCLC cells
The protocols in transfection of primary NSCLC cells are similar to the instruction in mentioned above. The transfection with lentivirusmediated BCL-9 and NC shRNA (GeneChem, Shanghai, China) was performed according to Liposome Transfection based on the standard instruction as mentioned above. The primary NSCLC cells were cultured in DMEM/F-12 growth medium with high glucose (25 mmol/L) in culture flasks (~10,000-50,000 cells) and 20% fetal bovine serum and was passed for 2-4 generations until the viable cell percentage was over 70% according to Trypan blue staining. And then we seeded on 96-well plates (5000 cells/well) and incubated overnight. On the second day, the cells were transfected with lentivirus vector constructed by BCL9-shRNA at a fusion rate of over 80% (CCTCTGTTGAATATCCCTGGAA) or NC-shRNA (AGCGTGGGTGGGGTCCGTCC) for 12-24 h by using Lipofectamine reagents (Invitrogen). Likewise, successful transfection in primary NSCLC cells was identified by the expression of green fluorescence. In total, > 70-80% cells were flashed with green fluorescence under a fluorescence microscope, thereby indicating a successful establishment of the cell models though the transfected effectivity is slight lower than in NSCLC cell lines, classified as Primary-NC and Primary-BCL9-KD (knockdown), respectively.
Quantitative PCR
Total RNA was isolated from the NCI-H460 cells and A549 cells that were either transfected with lentivirus-mediated shRNA or not, using TRIzol Reagent (Invitrogen). Total RNA was reversely transcribed using hexamer primer and Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) for analysis of the transcription levels. Subsequent qRT-PCR was performed by using SYBR Green PCR master mix. GAPDH was used as an endogenous control for mRNA expression. The relative expression level was calculated by the 2 −ΔΔCt analysis method. The sequence of primers for quantitative PCR in this study are presented in Table 1 .
Western blot
Western blot was performed using the following primary antibodies: β-catenin (ab32572, 1:10000), phosphorylated β-catenin (ab27798, 1:1000), BCL9 (ab37305, 1:1500), ABCG2 (ab24115, 1:100), CD133 (ab19898, 1:1000), Sox2 (ab92494, 1:2000), CSK3β (ab93926, 1:2000) .
ZEB1 (ab17315, 1:1000), and Snail (ab53919, 1:5000). The primary antibodies were obtained from Abcam (Cambridge, UK). The cells were lysed using the RIPA lysis buffer (Thermo Fisher Scientific™, America, 89,900) containing Halt phosphatase inhibitor (10 μL/ml RIPA buffer, 1:50, Thermo Fisher Scientific, 78420) for 10 min followed by spin for 10 min (14,000 ×g) at 4°C and the concentration of the protein lysates was measured using BioTek EPOCH (Winooski, VT, USA). Equivalent protein lysates were separated by SDS-PAGE gel (10%) electrophoresis and then transferred to nitrocellulose membranes. The membranes were first blocked with 5% dried milk in TBST (Tris-buffered saline with Tween 20) for 1 h at 27 ± 2°C, and then probed with the indicated primary antibody overnight (4°C). Subsequently, the blots were washed thrice with 1× TBST followed by incubation with the secondary antibodies for 2 h at 27 ± 2°C. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; anti-GAPDH from Kangcheng, Inc., Shanghai, China) was used as an internal control. After washing thrice with TBST, the proteins signal were detected using the enhanced chemiluminescence system (ECL; Pierce Biotechnology, IL, USA) and Alpha InnotechFluorchem SP (San Leandro, CA, USA) and were quantified according to the loading control. The GAPDH was regarded as the control protein in immunoblot assays.
Wound-healing assay
Cell migration ability was determined by the wound healing assay. Cells were seeded on six-well plates. After 24 h, straight lines were drawn by scraping the confluent cells with a 20 μL pipette tip and ruler. The medium and floating cells were carefully removed, the adherent cells were washed away by PBS three times, and continued in culture with a serum-free medium. Following a 24 h incubation period, the wound-healing process was monitored under a phase-contrast microscope, the migration distance was measured, and representative images were obtained at 0 and 24 h.
Cell invasion ability assay
Transwell assay was performed to assess the cell invasion ability using the HTS transwell-24 system (Corning, NY, USA). For the assay, 100 μL of 5 × 10 4 cells were seeded onto the upper chamber and the lower chamber was filled with 600 μL medium. The cells in the upper chamber that was without serum, had a tendency to pass through the membrane into the lower compartment with a culture medium containing 10% FBS, making it possible to estimate the ability of the migration and invasion. After incubation for 24 h, the cells which passed through the membrane and were in the lower compartment were stained with Giemsa stain, fixed with 4% paraformaldehyde on the slides, and counted under a light microscope.
Cell immunofluorescence analysis
The cells that adhered to the coverslips were fixed with 4% paraformaldehyde, permeabilized with Triton X-100 (0.2%) for 15 min, and then blocked with PBS with 3% bovine serum albumin for 30 min at 27 ± 2°C. After incubating with rabbit anti-β-catenin (ab32572, Abcam, Cambridge, UK) overnight, the coverslips were incubated with secondary antibodies for 30 min and treated with DAPI (Sigma, MO, USA) for nuclear staining. Finally, the cells were examined using confocal laser scanning microscopy (Leica, Wetzlar, Germany).
MTT assay
MTT assay was used to determine the cell viability [14] . Cells were seeded in 96-well plates (2 × 10 3 cells/well), and cisplatin at the concentration of 100 μM was added for 2-4 days. The cells were cultured with 100 μL sterile MTT dye (Sigma, Saint Louis, MO) for 4 h, followed by the removal of medium and supplementation with 150 μL of DMSO (dimethyl sulphoxide). After shaking, the absorbance was measured.
Luciferase assay
Promoter sequences of human β-catenin were amplified using specific PCR and cloned into PGL3-Basic vectors (provided by Promega, WI), which were then placed in the upstream of luciferase reporter gene Firefly and Renilla based on the standard procedures. Using Nucleofection, the vector carrying a sequence of target promoter containing the luciferase reporter gene and sequence of putative transcription factor, BCL9 mRNA, were transfected into HEK293 cells with either scramble sequence (negative control). Then we used the dual luciferase assays to identify the specific transcription regulation of BCL9 to target promoters of beta-catenin. Two days later, the cells subjected to lysis and dual luciferase assay kits (provided by Promega, WI) was used to examine Firefly luciferase and Renilla activity. Firefly luciferase activity was used for normalization of the results, and fold over control was employed to describe the results.
Isolation and culture of primary NSCLC cells
The protocol of digestion and isolation of primary NSCLC cells was performed according to a previous study [15] . Primary NSCLC cells were isolated from a patient's diagnosed central squamous cell lung carcinoma and with platinum chemotherapy resistance. After dissection and removal of adherent para-carcinoma tissue, carcinoma tissue was rinsed with PBS and epithelial cells were gently scraped with a scalpel. Harvested cells were incubated in 25 cm 2 culture flasks, additionally coated with collagen, in DMEM/F-12 growth medium (Gibco, Carlsbad, CA) containing 20% fetal calf serum (Biowest Ltd., Ringmer, UK), antibiotics (Pen/Strep) and antimycotic (Fungizone®, Gibco). One day later, cells were washed and grown in BEGM (bronchial epithelial cell growth medium) (Lonza, Basel, Switzerland) to sub-confluency. Cells at passages two to four were used for experiments. Homogeneity of cultured primary NSCLC cells was analyzed by trypan staining for evaluation of cell viability (≥98% of cells stained positive). The study was approved by the medical ethic committee of Tianjin Medical University Cancer Institute and Hospital and we obtained the informed consent of the patients.
Statistical analysis
The data were showed as mean ± standard error of the mean (SEM). Every experiment was repeated triplicate. Unpaired t-tests were used to determine the differences between two groups. p < 0.05 was considered to be statistically significant. All analyses were performed with the SPSS 13.0.
Results
The knockdown of BCL9 by specific shRNA attenuates metastasis and invasion in cisplatin-resistant (CR)-NSCLC cells
Numerous researches have reported that BCL9/9l promoted cell proliferation and metastasis via the activation of β-catenin [13] . The inhibition of BCL9 could be a potential therapeutic target in the repression of metastasis and invasion in carcinoma because of the absence of aberrant expression in normal tissues [13] . In order to investigate whether the mechanism occurred in NSCLC, we referred to microarray results from a previous study associated with CR cells by comparison of transcription difference between wild type H460 and cisplatin-induced CDDP-R H460-NCI cells) and found that BCL9 expression was enriched in CR cell lines. Further, we validated the discovery by quantitative real time PCR (qRT-PCR) in another drug-resistant NSCLC cell line, A549/ DDP and wild type H460 cell line (sensitive to cisplatin in vitro experiments) and found an increased expression of BCL9 in the A549/DDP cell line compared with that in the H460 cells (Fig. 1A) . To investigate the role of BCL9 in regulating metastasis and invasion, we silenced the expression of BCL9 by transfection of the lentivirus-mediated shRNA (Fig. 1B and C) and determined the influence on metastasis and invasion. We observed that following the transfection with shRNA, the A549/DDP cells displayed significantly reduced migration distance and fewer cells in the lower chamber compared to the negative control ( Fig. 1D and E) . The results demonstrated that the BCL9 knockdown could have a negative effect on the ability of metastasis and invasion in drug-resistant NSCLC cell lines as presented in colon carcinoma and multiple myeloma. The correlation between BCL9 expression and Wnt/β-catenin having been proved in several existing studies [16] , we measured the expression of β-catenin by quantitative Real-time PCR. We found that the β-catenin expression increased in A549/DDP cells compared with that in the wild type H460 cells and reduced expression of β-catenin after the silence of BCL9 by shRNA induction in A549/DDP cells ( Fig. 2A) , which suggested that BCL9 knockdown inhibited the expression of β-catenin and blocked the Wnt classical pathway. We found the BCL9 could not directly influence the expression of β-catenin by interact with the promoter of beta-catenin as transcription factor (TF) (Fig. 2B) . The data demonstrated that the BCL9 could affect the intracellular transcription levels of β-catenin via complicated mechanisms independent on the direct effect as TF. The Wnt/β-catenin classic pathway plays a key role in tumor progression, especially in EMT. The abnormal activation of the pathway will results in metastasis and invasion. Therefore, we detected the expression of genes that were related to EMT, including zinc finger E-box-binding homeobox 1 (ZEB1) and Snail [7, 8] (Fig. 2C and D) . Indeed, we found a reduction in the expression of these genes after treated by shRNA compared with that the non-silencing-shRNA control or the blank vector. The results partially proved the assumption that BCL9 inhibited EMT and induced the lazy biological phenotype by blocking the Wnt/β-catenin.
The BCL9 knockdown inhibited nuclear translocation of β-catenin
The Wnt pathway is involved in numerous physiopathologic process, including tumorigenesis. In the absence of Wnt ligands, β-catenin binds to APC (adenomatous polyposis coli), GSK3β (glycogen synthase kinase 3β), and Axin forms a destruction complex that phosphorylates β-catenin, resulting in its degradation instead of promoting its nuclear translocation [16] . Therefore, phosphorylation of β-catenin represented the extent of the inhibition of Wnt pathway because of the phosphorylated inactive forms. As shown in Fig. 3A and B, BCL9 knockdown reduced the expression of beta-catenin and seemed to suggest the potential phosphorylation of β-catenin according to the result presented in the Fig. 3 and Supplementary Table 1. Because we have not verified directly the decrease of phosphorylated β-catenin after block out of BCL9, the potential increase of phosphorylation of β-catenin indeed need to be further confirmed. Furthermore, we observed the co-localization distribution of the cell nucleus with β-catenin by the immunofluorescence assay (Fig. 3C) . The fluorescence intensity significantly decreased in the nuclear region after BCL9 knockdown, which proved that the development of nuclear translocation was reduced in the event that the drug-resistant NSCLC cell lines were transfected with the BCL9-shRNA to silence its transcription. These results demonstrated that the BCL9 silencing reduced the accumulation in nuclear region and seemed to inhibit the Wnt pathway by phosphorylation of β-catenin in addition to inhibition of the transcription.
Effect of Wnt/β-catenin pathway agonist on the CR NSCLC cell line after BCL9 silencing
Further, the effect of Wnt pathway in the inhibition of migration after the silencing of BCL9, was ascertained by investigating whether the migration ability was restored in the presence of a Wnt signaling agonist. We utilized CP21, a highly selective inhibitor of GSK3β, to activate the Wnt signaling and explore the effect on migration in A549/ DDP cell line after treatment with shRNA. The application of CP21 resulted in significant partial recovered the expression of β-catenin after knockdown of BCL9 compared (Fig. 4A) . Furthermore, the migration distance and the number of cells that invaded into the lower chamber were significantly increased compared with the group that was not treated with the agonist (Fig. 4B and C) , proving that CP21 could attenuate the negative regulation of BCL9 silencing to EMT. The ability of metastasis and invasion was partially restored after the treatment with CP21, which proved that the Wnt pathway plays a crucial role in reducing cell migration after BCL9 silencing in CR NSCLCs.
BCL9 knockdown plays a critical role in the recovery of sensitivity to cisplatin and cellular proliferation
We have demonstrated that overexpression of BCL9 might be the key factor contributing to EMT in drug-resistant NSCLC cells. However, it is still ambiguous whether BCL9 knockdown can change the drugresistant phenotype of A549/DDP cell line. Knockdown of BCL9 blocked the Wnt pathway in which it has multiple effects on tumor biology, including metastasis, cell proliferation, stemness of cancer cells, and neovascularization in the carcinoma microenvironment [11] . Therefore, we deemed that BCL9 knockdown not only negatively regulated the EMT but other biological mechanisms associated with poor prognosis. In accord, we considered the recovery of chemotherapeutic sensitivity as a possible additional phenotypic conversion, irrelevant to the reduced EMT, after blocking the Wnt signaling in A549/ DDP cell line. We detected cisplatin sensitivity by MTT assay and found that the pre-treatment of lentivirus-mediated shRNA significantly inhibited the growth of drug-resistant cell lines compared with the control group (Fig. 5A) , which suggested that the recovery of sensitivity occurred in the condition where the drug-resistant cells were pretreated with shRNA to inhibit the expression of BCL9. Furthermore, we examined the expression of the gene markers that were related to cancer cell stemness, such as Sox2, CD133, and ABCG2 [17, 18] . A   Fig 3. The effect of BCL9 silencing on the Wnt/β-catenin signaling pathway A. Expression of total β-catenin and that of phosphorylated β-catenin after silencing BCL9 in A549/ DDP cells measured by western blotting. Total β-catenin expression is decreased after treated by the BCL9 specific shRNA. GAPDH served as the control. The quantitative analysis of relative expression presented as the lower fig. B . Phosphorylated β-catenin to total β-catenin ratio after silencing BCL9 in A549/DDP cell. C. Representative images of the reduced translocation of β-catenin after silencing BCL9 examined by immunofluorescent assays. The reduced colocalization of cell nucleus (blue) with β-catenin (green) observed in A549/DDP cell after treated by the BCL9 specific shRNA. *p < 0.05, ** p < 0.01 compared with control. The data were presented as Mean ± SD and these data used for calculation of P value and standard error were derived from five independent experiments. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) decrease in the expression of these marker genes was observed, which demonstrated that BCL9 might be involved in the chemotherapeutic resistance by the enhancement of stemness of cancer cells (Fig. 5B) . These discoveries illustrated that the silencing of BCL9 influenced the expression of β-catenin to regulate various tumor biological behaviors, including EMT, acquisition of cancer stemness, cell proliferation, and drug resistance.
The knockdown of BCL9 in primary NSCLC cell improved the aggressive biological behaviors
To verify the conclusion we draw from experiments in NSCLC cell line, we repeatedly performed vital experiments in primary NSCLC cells from a patient. We verify the decreased expression of total beta-catenin after administration of BCL9-shRNA (Fig. 6A) . We found the BCL9 shRNA significantly repressed the migration and invasion in vitro experiments ( Fig. 6B and C) . Meanwhile, the sensitivity to cisplatin was also improved after administration of BCL9-shRNA (Fig. 6D) , which Fig. 4 . Wnt/β-catenin pathway signaling agonist, CP21 blocked partly the negative effect of BCL9 silencing on the invasion and migration in A549/DDP cell lines. A. CP21 significantly further partially recovered the expression of β-catenin after BCL9 silencing. The expression levels were measured by Western blot. B. Representative figures and statistic results of cells number that invaded into the lower chamber among control group, sole shRNA group and shRNA + CP21 group and quantitative analysis of cells in lower chamber based on 5 independent experiments. C. Representative figures and statistic results of migration distance among control group, sole shRNA group and shRNA + CP21 group and quantitative analysis based on 5 independent experiments. Migration distance in shRNA+CP21 group was significantly increased compared with the group not treated by agonist. *p < 0.05, ** p < 0.01 compared with control. The red line represented the beginning site and the yellow line show the terminal site after 24 h. The statistical data were presented as Mean ± SD and these data used for calculation of p value and standard error were derived from five independent experiments. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
suggest that the blockage of BCL9 would lead to the recovery of chemotherapy resistance. The data offer evidence that the BCL9 knockdown indeed improved the tumor biology in both cell lines and primary NSCLC cells, which suggested that the BCL9 knockdown might be a potential therapeutic strategy for chemotherapy-resistance NSCLC.
Discussion
According to different clinical guidelines, chemotherapy has been recommended as a standard therapy for NSCLC with the progression in chemotherapeutic drugs and clinical research associated with NSCLC [19, 20] . However, development of chemotherapeutic resistance with the occurrence of drug-resistant tumor cell lines has been a major challenge in NSCLC chemotherapy, which continues to worry clinical The statistical data were presented as Mean ± SD and these data used for calculation of P value and standard error were derived from five independent experiments. The representative images of Western blot results and the quantitative analysis based on relative expression levels of five independent experiments. *p < 0.05, ** p < 0.01 compared with control.
physicians. The underlying mechanism of chemotherapeutic resistance is rather complicated, involving variations in genes that are related to cell proliferation, metastasis, and cell cycle control [21, 22] . A previous study has reported that cisplatin resistance might be correlated to EMT [23] . In another study on TGF-β-induced EMT, increased ability of cell proliferation and migration was observed, but a slight change in the population of cancer stem cells (CSCs) demonstrated a neutral effect on the cancer cell stemness in TGF-induced EMT [24] . The finding demonstrated that TGF-β induced EMT could influence various biological mechanisms in tumors, but independent of the enhancement of stemness of cancer cells. Unexpectedly, the EMT induced by TGF-β eventually has a positive influence on the chemotherapy sensitivity, but the cause needs to be further investigated.
There are an increasing number of researches about the key role of EMT in the programming of drug resistance. Mani et al. showed that a CSC-like cancer cells could be induced by the EMT programming, which suggested that EMT programming promoted the phenotypic differentiation to mesenchymal cells and the formation of CSC-like cancer cells, with a tendency for metastasis and the occurrence of drug resistance [25, 26] . Both metastasis and drug resistance have a tight Cell proliferation and drug sensitivity evaluated by MTT assay after treatment with CDDP (100 μM) among different groups in primary NSCLC cells. The statistical data were presented as Mean ± SD and these data used for calculation of P value and standard error were derived from three independent experiments. correlation with the CSCs. Cai et al. found the key molecular mechanism underlying chemotherapy resistance, in which miR-128 induced enhancement of cancer cell metastasis by simultaneously activating TGF-β and Wnt pathway and the acquisition of cancer stemness [5] . In our study, the increased expression of β-catenin was observed by qRT-PCR in chemotherapy-resistant cell lines. BCL9 was considered as the crucial co-activator for β-catenin transcription, which suggested that the BCL9 has a significant effect on biological behavior of tumors including metastasis, apoptosis, and chemotherapy resistance related to classic Wnt/β-catenin pathway. This was different from the aforementioned investigation about sole TGF-β induced EMT characteristic of any independent effect on cancer stemness. In a previous study, the dysregulation of Wnt/β-catenin resulted in the increased expression of EMT marker gene, and the upregulation of the stemness marker in adenocarcinoma and intestinal epithelial tissues [12] . The connection between EMT and chemotherapy sensitivity has difference in a distinct induced EMT model, as the discrimination between TGF-β induced EMT and activation of Wnt signaling induced depicted as above mentioned. The effect of sole EMT regardless of other biological behavior of tumor including the acquisition of stemness on chemotherapy sensitivity could still be explored. In our study, we proved that BCL9 promoted the EMT and other biological behavior in CR NSCLC cell line. BCL9 knockdown not only attenuated the migration of drug-resistance but also restored the cisplatin sensitivity, which might be attributed to the repression of CSCs. BCL9 knockdown in cisplatin-resistant A549 cells that characteristic of higher expression of BCL9 compared to the wild type H460 cells sensitive to cisplatin lead to the reduction of intracellular betacatenin levels as expected. And the reduction of beta-catenin and inhibition of Wnt/β-catenin signaling in cisplatin-resistant A549 cells would further improve the biological behaviors, including the migration, invasion, cancerous stemness and chemotherapy sensitivity by blocking the EMT. The EMT via the activation of Wnt pathway and subsequently acquisition of cancer cell stemness synergistically accelerated the metastasis and drug-resistance, which eventually might result in the poor prognosis in those patients with NSCLC. In the present study, we also found the BCL9 have positive influence on the expression of β-catenin in drug-resistant NSCLC cells. It is different from the findings in other cancerous cells that the BCL9 mainly aggravated the transcription activity of Wnt signaling via binding to the N-terminal domain of beta-catenin. We found that the BCL9 not only drove the pathologic β-catenin-mediated transcription of some oncogenes but also directly inhibition of nuclear translocation. The change of phosphorylation of β-catenin needs to further verify though we have observed the increased ratio of p-β-catenin to total β-catenin in 549 cell line. However, we have not found the increased ratio of p-β-catenin to total β-catenin in NSCLC primary cells. We only found the decreased expression of beta-catenin in primary NSCLC cells. We hypothesized that these results might be attributed to the instinctive and unavoidable difference between in cell lines and primary cells. Some systemic factors might result in the inconsistence in primary NSCLC cells, including the cell digestion, medium, cell viability and individual cancerous heterogeneity. The involved underlying mechanism and signaling pathway need to be further explored in following studies because we did not observe that the BCL9 could serve as a transcription factor directly promoting the expression of beta-catenin by simple dual luciferase assays. And the CP21, an agonist of Wnt/beta-catenin could not increase the transcription levels of beta-catenin but it might be able to enhance the stability and intracellular levels of beta-catenin via the inhibition of GSK3β. Therefore, the improvement of aggressive biological behaviors of cancerous cells dependent on the BCL9 knockdown and was partially diminished after administration of CP21.
Some studies in a variety of malignant tumors hold the ideas that selective binding of BCL9/9L to the N-terminal domain of β-catenin enhanced its transcription by formation of the β-catenin/BCL9 complex [27, 28] . But the phenomenon that overexpression of BCL9 occurs in NSCLC cells and promotes the transcription of β-catenin, leading to an increased proliferation, migration, and invasion of tumors in our study. Previous study found that the deletion of BCL9 in murine model has no effect on the normal gut function and intestinal epithelial development, which demonstrates that BCL9 might not be harmful in normal tissues [27] . Therefore, silencing BCL9 expression might be a potential rational approach to repress pathological activation of Wnt signaling by selective destruction of the β-catenin/BCL9 complex. In a previous study on colon carcinoma, the ablation of BCL9/β-catenin obviously promoted the differentiation of cancer cells, reduced tumorigenicity, and eliminated the EMT in colorectal tumor cells, but did not abrogate the ability for cell proliferation. Further, also identified the feasibility of BCL9 expression levels in clinical assessment according to the fact that the BCL9/9L KO signatures in colon tumor tissue from patients have positive influence on progression-free survival [12] . Some remarkable studies have demonstrated the available strategy that BCL9/β-catenin might be the therapeutic target in destruction of stemness and repression of tumorigenicity. Furthermore, the overexpression of BCL9 mainly occurred in the tumor tissue but was absent in normal cell component and it might be the reason why the deletion of BCL9 has no adverse influence on the normal physiological function and tissue homeostasis [11, 12, 27] . In our study, we observed that the increased expression in CR-NSCLC cell lines compared with the wild type cell line, characterized by sensitivity to chemotherapy drug, which might suggest that the BCL9 knockdown has more obvious effect on the CR-NSCLCs compared to the sensitive phenotype. In combination with the aforementioned effect of blocking Wnt/β-catenin pathway on multiple biological mechanisms of tumors, including that of stemness of cancer cells, drug resistance, and EMT programming, the selective inhibition of β-catenin by BCL9 knockdown repressed the EMT and stemness, which might lead to the recovery of sensitivity in our study.
Conclusions
In these pre-existing investigations, the role of BCL9/9L in tumor biology was clarified in colorectal carcinoma and multiple myeloma. There were no studies about the role of BCL9 in NSCLC cell lines, while we found the increased expression of BCL9 in cisplatin-resistance NSCLC cells, which prompted us to investigate the effect of BCL9 in NSCLC drug-resistance. We verified that the formation BCL9/β-catenin complex in NSCLC drug-resistant cell lines might lead to the augmentation of stemness and chemotherapy resistance. The BCL9 silencing repressed the transcription of β-catenin, which blocked the Wnt/β-catenin pathway. In conclusion, we found the BCL9 overexpression in NSCLC drug-resistance cell lines and that it might be the rational and promising therapeutic target in patients with cisplatin resistance.
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